The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer.
Monica M GrovaPaula D StrassleEmma E NavajasKristalyn K GallagherDavid W OllilaStephanie M Downs-CannerPhilip M SpanheimerPublished in: Annals of surgical oncology (2020)
Five-year survival in M0 IBC is 51.6%. Positive nodes after NAC varied by subtype and clinical N status but is sufficiently high and provided meaningful prognostication in all subtypes to support continued routine pathologic assessment. Future study is warranted to identify reliable, less morbid, methods of staging the axilla in IBC patients appropriate for deescalation of axillary surgery.
Keyphrases
- neoadjuvant chemotherapy
- sentinel lymph node
- lymph node
- locally advanced
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- early stage
- minimally invasive
- pet ct
- squamous cell carcinoma
- rectal cancer
- oxidative stress
- prognostic factors
- bariatric surgery
- peritoneal dialysis
- young adults
- current status
- clinical practice
- weight loss